Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy

American Journal of the Medical Sciences

Volumn 336, Issue 3, 2008, Pages 288-290

  Antonelli, Alessandro ^a   Fallahi, Poupak ^a   Tolari, Simone ^a   Ferrari, Silvia Martina ^a   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Graves' ophthalmopathy; Radioiodine; Thyroid cancer; Thyroidectomy; Thyrotropin receptor autoantibody

Indexed keywords

AUTOANTIBODY; CALCITONIN; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN; THYROTROPIN-BINDING INHIBITORY IMMUNOGLOBULIN;

ADULT; ARTICLE; ASPIRATION BIOPSY; CALCITONIN BLOOD LEVEL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE DISCOMFORT; EYE EXAMINATION; EYELID MOVEMENT; EYELID PAIN; EYELID RETRACTION; FEMALE; HISTOLOGY; HUMAN; LIOTHYRONINE BLOOD LEVEL; PATHOGENESIS; PHYSICAL EXAMINATION; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING; BLOOD; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; POSTOPERATIVE COMPLICATION; REMISSION; THYROID TUMOR;

CARCINOMA, PAPILLARY; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REMISSION, SPONTANEOUS; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 55249118819     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31815b21ab     Document Type: Article

References (19)

1. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003;148:1-9.
2. Bahn RS. Thyrotropin receptor expression in orbital adipose/ connective tissues from patients with thyroid-associated oph-thalmopathy. Thyroid 2002;12:193-5.
3. Bahn RS. Understanding the immunology of Graves' oph-thalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am 2000;29:287-96, vi.
4. Ludgate ME, Vassart G. The thyrotropin receptor as a model to illustrate receptor and receptor antibody diseases. Baillieres Clin Endocrinol Metab 1995;9:95-113.
5. Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-gamma- inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome prolif-erator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006;91:614-20.
6. Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997;7:579-85.
7. Antonelli A, Miccoli P, Ferdeghini M, et al. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995;5:25-8.
8. Antonelli A, Ferri C, Fallahi P, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004;97:499-506.
9. Rubio IG, Perone BH, Silva MN, et al. Human recombi-nant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. Thyroid 2005;15:134-9.
10. Dunkelmann S, Wolf R, Koch A, et al. Incidence of radiation-induced Graves' disease in patients treated with radio-iodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging 2004;31:1428-34.
11. Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005;153:49-55.
12. Kumar A, Shah DH, Shrihari U, et al. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 1994;4:199-202.
13. Franke WG, Zophel K, Wunderlich G, et al. Thyroid peroxidase (TPO) as a tumor marker in the follow-up of differentiated thyroid carcinomas with surgical and ablative radioiodine therapy. An assessment after evaluation. Anti-cancer Res 1999;19:2711-6.
14. Katz SB, Garcia AJ, Niepomniszcze H. Development of Graves' disease nine years after total thyroidectomy due to follicular carcinoma of the thyroid. Thyroid 1997;7:909-11.
15. Rogers PB, Gupta N, Rose GE, et al. Thyroid eye disease associated with athyria. Br J Ophthalmol 2000;84:439.
16. Berg G, Andersson T, Sjodell L, et al. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. Thyroid 2005; 15:1389-94.
17. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51.
18. Pacini F, Mariotti S, Formica N, et al. Thyroid autoan-tibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh) 1988;119: 373-80.
19. Garrity JA, Bahn RS. Pathogenesis of graves ophthalmop-athy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006;142:147-53.